Free shipping on all orders over $ 500

Mivebresib

Cat. No. M5258
Mivebresib Structure
Synonym:

ABBV-075

Size Price Availability Quantity
2mg USD 100 In stock
5mg USD 140 In stock
10mg USD 265 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

In vitro: ABBV-075 exhibits robust single agent activity in cell viability assays across cancer cell lines derived from solid tumors, leukemia and lymphomas. It could disrupt cell cycle control leading to G1 arrest followed by senescence, inhibit oncogenesis drivers leading to apoptosis, and potentially target tumor microenvironment to provide additional therapeutic benefit.

In vivo: ABBV-075 has comparable or superior efficacies to standard of care agents in flank xenograft mouse models of non-small-cell and small cell lung cancers, pancreatic, breast, prostate, head & neck cancers, multiple myeloma, diffuse large B cell lymphoma and leukemia.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 459.47
Formula C22H19F2N3O4S
CAS Number 1445993-26-9
Purity 99.93%
Solubility 85 mg/mL in DMSO
Storage at -20°C
References

Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies.
Bui MH, et al. Cancer Res. 2017 Apr 17;1793.2016. PMID: 28416490.

Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.
Faivre EJ, et al. Mol Cancer Res. 2017 Jan;15(1):35-44. PMID: 27707886.

Related Epigenetic Reader Domain Products
AZD5153

AZD5153 is a potent bivalent triazolopyridazine based Bromodomain and Extraterminal (BET) Inhibitor, with IC50 value of 5 nM.

MS417

MS417 (also known as GTPL7512) is a potent and selective BRD4 inhibitor, which binds to BRD4-BD1 and BRD4-BD2 with IC50s of 30 and 46 nM, respectively.

FL-411

FL-411 is a selective BRD4 inhibitor.

dBET6

dBET6 is a highly potent, selective and cell-permeable degrader of BET with an IC50 of 14 nM.

dBET1

dBET1 is a potent BRD4 protein degrader with an EC50 of 430 nM.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Mivebresib, ABBV-075 supplier, Epigenetic Reader Domain, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.